• by:
  • November 30th, 2020
  • Category:

ESTRO 2020


Presentation of our work on the prospective validation of a radiomics signature for chemoradiotherapy lung cancer patients

ESTRO 2020

Presentation of our work on the prospective validation of a radiomics signature for chemoradiotherapy lung cancer patients.

Radiomics’ CSO Sean Walsh presented our work on the “Prospective Validation of a Radiomics Signature for Chemoradiotherapy Lung Cancer Patients” at the ESTRO 2020 meeting.

The prospective clinical evidence for a radiomics signature predicting overall survival is the first one of her kind. Performance metrics for favorable vs unfavorable outcomes in NSCLC patients treated by chemoradiotherapy were consistent between model development, internal validation, external validation, and prospective validation across more than 1000 patients in total. Furthermore, Signature-0 can stratify with high accuracy patients who are very favorable vs very unfavorable.
ESTRO 2020